8-K: Biote Corp. Reports Strong Q1 2025 Financial Results Driven by Vertical Integration and Announces Organizational Restructuring

Biote Corp. announces its Q1 2025 financial results, highlighting revenue growth, increased gross profit margin, and a strategic organizational restructuring to drive sustainable growth.

Summary

• Biote Corp. reported its financial results for the first quarter ended March 31, 2025.
• Total revenue increased by 4.7% year-over-year to $49.0 million, driven by a 25.5% increase in dietary supplements revenue.
• Procedure revenue decreased by 3.6% year-over-year.
• Gross profit margin improved to 74.3% compared to 71.3% in the prior year, primarily due to the vertical integration of the 503B manufacturing facility.
• Net income was $15.8 million, or $0.37 diluted earnings per share, compared to a net loss of $(5.7) million, or $(0.12) diluted loss per share, in the prior year period.
• Adjusted EBITDA was $13.8 million, with an Adjusted EBITDA margin of 28.1%.
• The company announced an organizational restructuring of its commercial teams, expecting to incur $0.6 to $0.8 million in pre-tax restructuring charges in the second quarter of 2025.
• Biote maintains its 2025 financial outlook, projecting revenue between $202 and $208 million and Adjusted EBITDA between $59 and $64 million.
• Procedure revenue is expected to increase approximately 2-4% from 2024, and dietary supplements revenue is expected to increase approximately 5-10% from 2024.
• For the second quarter of 2025, the Company expects revenue and Adjusted EBITDA to be similar to or slightly higher than that of the second quarter of 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the increase in revenue, improved gross profit margin, and significant turnaround in net income. The organizational restructuring is presented as a strategic move to drive future growth, further contributing to the positive outlook. However, the decrease in procedure revenue and increased sales and marketing expenses temper the overall sentiment slightly.

Positives

• Revenue increased by 4.7% year-over-year to $49.0 million.
• Gross profit margin improved to 74.3% due to vertical integration and cost management.
• Net income was $15.8 million, a significant turnaround from the previous year's net loss.
• Dietary supplement revenue increased by 25.5%, indicating strong growth in that segment.
• The company is proactively restructuring to drive sustainable growth and improve financial performance.

Negatives

• Procedure revenue decreased by 3.6% year-over-year, indicating a slowdown in that area.
• Operating income decreased from $10.4 million to $9.7 million due to increased sales and marketing expenses.
• Adjusted EBITDA and Adjusted EBITDA margin decreased compared to the prior-year period due to increased sales and marketing activities.

Risks

• The company faces risks related to the successful execution of its organizational restructuring.
• The company's success depends on the market acceptance of its dietary supplements.
• The company is subject to regulatory, economic, environmental, and competitive conditions.
• The company's ability to grow its business is subject to significant competition.
• The company's limited operating history and ability to protect its intellectual property pose risks.

Future Outlook

Biote maintains its 2025 financial guidance, projecting revenue between $202 and $208 million and Adjusted EBITDA between $59 and $64 million. Procedure revenue is expected to increase approximately 2-4% from 2024, and dietary supplements revenue is expected to increase approximately 5-10% from 2024. For the second quarter of 2025, the Company expects revenue and Adjusted EBITDA to be similar to or slightly higher than that of the second quarter of 2024.

Management Comments

• Biote's first quarter results benefited from efficiencies related to the vertical integration of our 503B manufacturing facility as well as growth in our dietary supplements business, said Bret Christensen, Biote Chief Executive Officer.
• Last year, Biote embarked on an ambitious plan designed to strengthen our competitive moat and broaden our capabilities to better serve the growing market for hormone optimization and therapeutic wellness.
• The strategic reorganization we are undertaking represents an important next step in Biotes evolution as we continue our mission to transform healthy aging and become the preferred single-source provider of evidence-based therapeutic wellness solutions.

Industry Context

Biote operates in the preventive health care market, specifically focusing on personalized hormone optimization and therapeutic wellness. The company's vertical integration and expansion of capabilities aim to strengthen its competitive position in this growing market.

Comparison to Industry Standards

• It's difficult to provide a direct comparison to industry standards without knowing the specific peer group Biote considers its competitors.
• However, companies like Thorne HealthTech and Life Extension also operate in the dietary supplements and wellness space.
• Comparing Biote's growth rate, gross margins, and EBITDA margins to these companies would provide a better understanding of its relative performance.
• Additionally, analyzing the growth rates of other companies in the hormone replacement therapy market could offer further insights.

Stakeholder Impact

• Shareholders can expect potential long-term value creation from the organizational restructuring.
• Employees are affected by the workforce reduction of 16 employees.
• Providers and patients may benefit from the enhanced value proposition and improved services.
• Suppliers and creditors may experience changes in business relationships due to the restructuring.

Next Steps

• The company will continue to implement its organizational restructuring plan.
• Biote will focus on driving new clinic growth and maximizing value from existing providers.
• The company will host a conference call to review the results and provide a business update.

Key Dates

Keywords

Biote, Financial Results, Q1 2025, Revenue, Adjusted EBITDA, Gross Profit Margin, Organizational Restructuring, Dietary Supplements, Hormone Optimization, Therapeutic Wellness